EQS-News: Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): 9 Month figures
Berlin, 8 November 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) increased sales by 25% to EUR 164.0 million in the first nine months of 2022. Net income of EUR 23.3 million was EUR 5.8 million lower than in the same period of the previous year, in which the sale and associated deconsolidation of the tumor irradiation device division generated one-off income of approximately EUR 9.4 million. Adjusted for this one-time effect, consolidated net income attributable to EZAG shareholders increased by around 18% year-on-year from EUR 19.7 million to EUR 23.3 million. This increase in earnings was due to favorable exchange rates as well as higher sales of industrial products and radiopharmaceuticals.
08.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1481113 |
End of News | EQS News Service |
|
1481113 08.11.2022 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Positive Community-Reaktionen für Eckert & Ziegler Strahlen- und Medizintechnik AG mit mehreren Buy-Einschätzungen, keine Sell-Einschätzungen.
Für Eckert & Ziegler Strahlen- und Medizintechnik AG sieht die Community ein Kursziel von 95 €, was mehr als das Doppelte des aktuellen Kurses von 41.36 € ausmacht.